[Use of intravenous immunoglobulins in Guillain-Barré syndrome].
The aim of the study was to assess the utility of intravenous integral molecule immunoglobulin treatment in Guillain-Barré syndrome. The etiopathogenesis of this syndrome is still unclear but it seems increasingly likely that immune phenomena are involved in the genesis of the neurological lesions. This would explain the efficacy of iv immunoglobulin treatment even if the effective mechanism of action can still only be hypothesised.